VYNE stockholders approve all proposals for merger with Yarrow Bioscience at special meeting

VYNE Therapeutics Inc.

Proposal 1 (issuance of shares >20% and change of control) approved: 15,915,017 for, 137,159 against.
Proposal 2 (reverse stock split 1:10-70) approved: 25,389,760 for, 550,694 against.
Proposal 3 (increase authorized shares from 150M to 300M) approved: 23,921,348 for, 2,013,526 against.
Proposal 4 (Yarrow 2026 Stock Incentive Plan) approved: 12,691,384 for, 3,358,164 against.
Proposal 5 (Yarrow 2026 Employee Stock Purchase Plan) approved: 13,131,018 for, 2,909,493 against.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.